US 12,138,268 B2
Treatment of erectile dysfunction and other indications
Eric T. Fossel, Cambridge, MA (US)
Assigned to Strategic Science & Technologies, LLC, Cambridge, MA (US)
Filed by Strategic Science & Technologies, LLC, Cambridge, MA (US)
Filed on Apr. 18, 2023, as Appl. No. 18/136,306.
Application 18/136,306 is a continuation of application No. 17/126,159, filed on Dec. 18, 2020, granted, now 11,684,624.
Application 17/126,159 is a continuation of application No. 16/846,682, filed on Apr. 13, 2020, granted, now 10,898,489.
Application 16/846,682 is a continuation of application No. 16/196,037, filed on Nov. 20, 2018, granted, now 10,682,357.
Application 16/196,037 is a continuation of application No. 15/652,336, filed on Jul. 18, 2017, granted, now 10,172,865.
Application 15/652,336 is a continuation of application No. 15/342,309, filed on Nov. 3, 2016, granted, now 9,737,543.
Application 15/342,309 is a continuation of application No. 15/290,504, filed on Oct. 11, 2016, granted, now 9,675,619.
Application 15/290,504 is a continuation of application No. 15/159,926, filed on May 20, 2016, granted, now 9,492,458.
Application 15/159,926 is a continuation of application No. 13/977,461, granted, now 9,463,158, previously published as PCT/US2011/067993, filed on Dec. 29, 2011.
Application 15/159,926 is a continuation of application No. 12/812,187, granted, now 8,604,081, previously published as PCT/US2009/003749, filed on Jun. 24, 2009.
Claims priority of provisional application 61/427,999, filed on Dec. 29, 2010.
Claims priority of provisional application 61/428,213, filed on Dec. 29, 2010.
Prior Publication US 2023/0372351 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/53 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/198 (2006.01); A61K 31/495 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 47/02 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/16 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0034 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 31/198 (2013.01); A61K 31/495 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 47/02 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/16 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01)] 20 Claims
 
1. A composition for topical delivery to the skin of a subject, comprising:
a nitric oxide donor comprising L-arginine and/or L-arginine hydrochloride at a concentration of about 2.5% to about 15% by weight;
xanthan gum at about 0.5% to about 1% by weight;
propylene glycol at about 1% to about 10% by weight;
a polysorbate surfactant at about 1% to about 4% by weight;
sildenafil and/or a salt thereof; and
an ionic salt, wherein the composition has an ionic strength of about 0.25 M to about 15 M.